- Home
- TCBX vs NMRA Comparison
TCBX vs NMRA Comparison
Compare TCBX & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | TCBX | NMRA |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.8M | 554.0M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | TCBX | NMRA |
|---|---|---|
| Price | $38.31 | $1.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $45.00 | $7.50 |
| AVG Volume (30 Days) | 61.6K | ★ 1.2M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.33 | 5.23 |
| EPS | ★ 0.88 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.99 | N/A |
| Revenue Next Year | $10.14 | N/A |
| P/E Ratio | $43.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.68 | $0.72 |
| 52 Week High | $43.84 | $3.65 |
Technical Indicators
Market Signals| Indicator | TCBX | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 39.26 |
| Support Level | $36.39 | $1.67 |
| Resistance Level | $38.86 | $1.81 |
| Average True Range (ATR) | 0.78 | 0.14 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 62.21 | 27.69 |
Price Performance
Historical ComparisonAbout TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates twenty branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, one branch in Ballinger, Texas, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.